Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension

Circulation Journal

Volumn 72, Issue 1, 2008, Pages 127-133

  Fujiwara, Maya ^a   Yagi, Hisato ^a   Matsuoka, Rumiko ^b   Akimoto, Kaoru ^b   Furutani, Michiko ^b   Imamura, Shin Ichiro ^b   Uehara, Ritei ^c   Nakayama, Tomotaka ^d   Takao, Atsuyoshi ^b   Nakazawa, Makoto ^b   Saji, Tsutomu ^d  

^a GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Activin receptor like kinase 1 gene; Bone morphogenetic protein receptor II gene; Pulmonary arterial hypertension

Indexed keywords

ACTIVIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN 2; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOME ANALYSIS; HERITABILITY; HETEROZYGOSITY; HUMAN; MALE; MUTATIONAL ANALYSIS; PROTEIN DOMAIN; PULMONARY HYPERTENSION; RECEPTOR GENE; AGE DETERMINATION; FAMILY HEALTH; GENETIC PREDISPOSITION; GENETICS; GENOMICS; METHODOLOGY; MUTATION; PATHOPHYSIOLOGY; PEDIGREE; PRESCHOOL CHILD; PULMONARY ARTERY; RENDU OSLER WEBER DISEASE;

ACTIVIN RECEPTORS, TYPE II; ADOLESCENT; AGE DETERMINATION BY SKELETON; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CHILD; CHILD, PRESCHOOL; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MUTATION; PEDIGREE; PROTEIN-SERINE-THREONINE KINASES; PULMONARY ARTERY; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 39849084288     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.127     Document Type: Article

References (42)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-725.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
3. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension: A national prospective study. Ann Intern Med 1987; 107: 216-223.
4. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA 3rd, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93-97.
5. th edn. New York: Dekker; 1997; 179-225.
6. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
7. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
8. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
9. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178.
10. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension: The International PPH Consortium. Nat Genet 2000; 26: 81-84.
11. Morisaki H, Nakanishi N, Kyotani S, Takashima A, Tomoike H, Morisaki T. BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension. Hum Mutat 2004; 23: 632-637.
12. Hogan BL. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev 1996; 10: 1580-1594.
13. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, et al. BMPR2 Haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92-102.
14. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-745.
15. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27: 121-132.
16. Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 2002; 13: 3055-3063.
17. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002; 11: 1517-1525.
18. Trembath RC, Thomson JR, Machado RD, Morgan NJ, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic terangiectasia. N Engl J Med 2001; 345: 325-334.
19. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003; 40: 865-871.
20. Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, et al. Transforming growth factor-β, receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005; 111: 435-441.
21. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
22. Schuster DP, Crouch EC, Parks WC, Johnson T, Botney MD. Angiotensin converting enzyme expression in primary pulmonary hypertension. Am J Respir Crit Care Med 1996; 154: 1087-1091.
23. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, et al. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: Increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 2003; 4: 27-30.
24. Tanabe N, Amano S, Tatsumi K, Kominami S, Igarashi N, Shimura R, et al. Angiotensin-converting enzyme gene polymorphisms and prognosis in chrome thromboembolic pulmonary hypertension. Circ J 2006; 70: 1174-1179.
25. Droma Y, Hanaoka M, Ota M, Katsuyama Y, Koizumi T, Fujimoto K, et al. Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation 2002; 106: 826-830.
26. Woods DR, Pollard AJ, Collier DJ, Jamshidi Y, Vassiliou V, Hawe E, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and arterial oxygen saturation at high altitude. Am J Respir Crit Care Med 2002; 166: 362-366.
27. Yoshida MC, Satoh H, Sasaki M, Semba K, Yamamoto T, Toyoshima K. Regional location of novel yes-related proto-oncogene, syn, on human chromosome 6 at band q21. Jpn J Cancer Res 1986; 77: 1059-1061.
28. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744.
29. Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, et al. The activin receptor-like kinase 1 gene: Genomic stmcture and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 1997; 61: 60-67.
30. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11: 719-725.
31. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20: 1433.
32. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67.
33. Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169: 994-1000.
34. Cottin V, Blanchet AS, Cordier JF. Pulmonary manifestations of hereditary hemorrhagic telangiectasia. Rev Mal Respir 2006; 23 (Suppl 2): 4S53-4S66.
35. Abdalla SA, Gallione CJ, Barst RJ, Horn EM, Knowles JA, Marchuk DA, et al. Primary pulmonary hypertension in families with heredtary haemorrhagic telangiectasia. Eur Respir J 2004; 23: 373-377.
36. Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, et al. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet 2005; 116: 8-16.
37. Abdalla SA, Cymerman U, Rushlow D, Chen N, Stoeber GP, Lemire EG, et al. Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia. Hum Mutat 2005; 25: 320-321.
38. Uehara R, Suzuki H, Kurokawa N, Urashima T, Fujiwara M, Matoba M, et al. Novel nonsense mutation of the BMPR-II gene in a Japanese patient with familial primary pulmonary hypertension. Pediatr Int 2002; 44: 433-435.
39. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-334.
40. Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS, et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: Mutations and manifestations. Am J Med Genet A 2006; 140: 463-470.
41. Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297.
42. Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: A clinical analysis. J Med Genet 1992; 29: 527-530.